Adopting Bispecific Agents for Multiple Myeloma into Practice

Laura R. Bobolts

Adopting Bispecific Agents for Multiple Myeloma into Practice

Interview with the Innovators

Multiple Myeloma Education

Videos

Featuring:

Laura R. Bobolts, PharmD, BCOP

Senior Vice President, Clinical Strategy and Growth
OncoHealth
Pompano Beach, FL

Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS

Director, Pharmacy Operations
Florida Cancer Specialists & Research Institute
Tampa, FL

Hakan Kaya, MD

Hematologic Oncologist and Senior Partner, Cancer Care Northwest
Director, Inland Northwest Myeloma/Lymphoma & Transplant Program
Clinical Professor, Elson S. Floyd College of Medicine, Washington State University
Clinical Professor of Medicine, University of Washington School of Medicine
Spokane, WA

Lisa Raff, PharmD, MSPharm, BCPS, BCOP

Vice President, Pharmacy Services
OneOncology
Nashville, TN

Yonatan Resnick, PharmD

Director, Pharmacy Clinical Services
New England Cancer Specialists
Scarborough, ME

In this third installment, Hakan Kaya, MD, Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS, and Yonatan Resnick, PharmD, discuss considerations for adopting bispecific therapies into regular multiple myeloma clinical practice.

Adopting Bispecific Agents for Multiple Myeloma into Practice

Featuring:

Related Articles

Stay In The Know

We Value Your Feedback! Tell Us How You Consume Content